Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative systemic therapy versus upfront CRS-HIPEC for resectable colorectal peritoneal metastases
NL-OMON21182Phase 3Recruiting
- Sponsor
- Catharina Ziekenhuis
- Start
- Jun 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine, oxaliplatin, fluorouracil, folinic acid, irinotecan and 1 more in colorectal cancer (CRC) (2 arms), sponsored by Catharina Ziekenhuis. Primary endpoints: Feasibility of accrual, Feasibility of perioperative systemic therapy and 5 more. Started Jun 2017; status: recruiting.
02
Drugs
capecitabineoxaliplatinfluorouracilfolinic acidirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON21182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21182.